Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find growth abroad while its home-market engine sputters. For shareholders watching OTCQB:DBCCF, that is both the attraction and the complication.
Exports Finally Have Some Muscle
International sales have now set records for three consecutive quarters. Year-to-date revenue from abroad is $32.3 million, up 92% and already ahead of all of 2025. Those are not cute little percentage gains off a dead base anymore. The company says it has more than 20 international customers under supply agreements, over 70 GACP cultivators and extractors onboarded, and a UK launch planned with Hilltop Leaf covering 15 General Admission and Standard Issue product lines plus six Hilltop-branded lines.
More important, this growth appears to carry better economics. Gross margin before fair value adjustments climbed to 52% from 47%, a fat 500-basis-point improvement. Management attributes much of that to international mix, and that passes the sniff test. Its AgMedica EU GMP operation has 60 tonnes of annual flower-processing capacity running at roughly 42% utilization, with room to double current processing capacity without material capital spending. That is the sort of operating leverage cannabis investors have been promised for years and rarely received.
Capacity Is Useful Only When Orders Convert
Still, nobody should confuse capacity with cash in the bank. Decibel expects backlog conversion to support sequential international growth through year-end and anticipates entering three new markets over the next six months. Fine. But export cannabis comes with regulatory hoops, customer concentration risk, shipping friction and currency exposure. A signed supply agreement is encouraging; repeat orders, clean collections and durable margins are the actual proof. Management has a credible runway here, but it has not earned the right to declare victory.
- Q3 adjusted EBITDA was $7.4 million, up only 2% year over year despite the revenue gain.
- Year-to-date adjusted EBITDA rose 30% to $22.2 million.
- Net income was $3.8 million, versus a $1.3 million loss a year earlier.
- Year-to-date net revenue reached $100.6 million, up 20%.
The Canadian Problem Cannot Be Shrugged Off
Domestic sales are the grit in the gears. Management says infused products became a smaller portion of the cannabis market, hurting General Admission, though Standard Issue grew. That explanation may be true, but it does not make the 6% quarterly decline any prettier. Overall market share slipped to 4.0% in Q3 from 4.3% in Q2, according to HiFyre data. Losing share while claiming brand strength is exactly where investors ought to get fussy.
There are real category footholds: Decibel ranks fourth among licensed producers in pre-rolls with 6.1% share and fourth in vapes with 8.4%. General Admission remains the top infused pre-roll brand at 16.2% share. Yet category rankings are not a substitute for a healthy domestic revenue trend. The plan—clearer brand roles, more disciplined pricing and promotions, better major-retailer execution, plus flower and standard pre-roll additions—sounds sensible. It also sounds like work that should have been underway sooner. Retail shelves are ruthless; a brand gap can become a habit fast.
International momentum is the prize, but domestic erosion is the bill sitting on the table.
Cash Flow Deserves the Hard Stare
The quarter produced $1.1 million of free cash flow, down 31% from last year. Worse, free cash flow for the first nine months was negative $8.7 million, versus positive $2.5 million previously. Decibel points to a $17.8 million increase in receivables and an $8.3 million reduction in payables tied to debt refinancing, calling the payables item one-time. Maybe so, but working capital has a nasty habit of exposing whether reported growth is translating into cash. This is not a footnote to wave away.
Management reaffirmed full-year guidance of $132 million to $137 million in net revenue and $28 million to $32 million in adjusted EBITDA. With $100.6 million of revenue and $22.2 million of adjusted EBITDA through nine months, the targets look reachable, assuming exports keep moving and collections behave. The company has also initiated steps to make a normal course issuer bid available, though the board does not expect material near-term purchases. Good: at this stage, operational execution beats symbolic buybacks every time.
One housekeeping item: this corrected release says an earlier version carried a non-working link, and that paragraph was removed. The correction does not identify changed operating figures, but investors should still read it as a reminder to separate the hard numbers from promotional fog. Decibel has a legitimate international growth story. The next test is whether that story can fund itself while the Canadian business stops leaking share.